The efficacy and safety of a third anti-TNF monoclonal antibody in Crohnâs disease after failure of two other anti-TNF antibodies-Reference-Cited by-同舟云学术

The efficacy and safety of a third anti-TNF monoclonal antibody in Crohnâs disease after failure of two other anti-TNF antibodies

Published:2010-01 Issue:1 Volume:31 Page:92-101
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:

Author:

ALLEZ M.,VERMEIRE S.,MOZZICONACCI N.,MICHETTI P.,LAHARIE D.,LOUIS E.,BIGARD M.-A.,HÃBUTERNE X.,TRETON X.,KOHN A.,MARTEAU P.,CORTOT A.,NICHITA C.,VAN ASSCHE G.,RUTGEERTS P.,LÃMANN M.,COLOMBEL J.-F.

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2036.2009.04130.x/fullpdf

Reference39 articles.

1. Tumour necrosis factor and Crohnâs disease;Van Deventer;Gut,1997

2. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohnâs disease. Crohnâs Disease cA2 Study Group;Targan;N Engl J Med,1997

3. Maintenance infliximab for Crohnâs disease: the ACCENT I randomized trial;Hanauer;Lancet,2002

4. Infliximab for the treatment of fistulas in patients with Crohnâs disease;Present;N Engl J Med,1999

5. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohnâs disease;Rutgeerts;Gastroenterology,1999

Cited by 101 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Difficult‐to‐treat inflammatory bowel disease: Effectiveness and safety of 4th and 5th lines of treatment;United European Gastroenterology Journal;2024-04-09

2. Controversies in the management of anti-TNF therapy in patients with Crohn’s disease: a Delphi consensus;BMJ Open Gastroenterology;2024-01

3. Management of Non-response and Loss of Response to Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease;Frontiers in Medicine;2022-06-15

4. Positioning biologics in the treatment of IBD: A practical guide – Which mechanism of action for whom?;Current Research in Pharmacology and Drug Discovery;2022

5. Primary Failure to an Anti-TNF Agent in Inflammatory Bowel Disease: Switch (to a Second Anti-TNF Agent) or Swap (for Another Mechanism of Action)?;Journal of Clinical Medicine;2021-11-15